- Home
- DRIO vs CVKD Comparison
DRIO vs CVKD Comparison
Compare DRIO & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRIO
- CVKD
- Stock Information
- Founded
- DRIO 2011
- CVKD 2022
- Country
- DRIO United States
- CVKD United States
- Employees
- DRIO N/A
- CVKD N/A
- Industry
- DRIO Medical/Dental Instruments
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- DRIO Health Care
- CVKD Health Care
- Exchange
- DRIO Nasdaq
- CVKD Nasdaq
- Market Cap
- DRIO 28.3M
- CVKD 33.7M
- IPO Year
- DRIO N/A
- CVKD 2023
- Fundamental
- Price
- DRIO $0.70
- CVKD $15.10
- Analyst Decision
- DRIO Strong Buy
- CVKD Strong Buy
- Analyst Count
- DRIO 2
- CVKD 1
- Target Price
- DRIO $2.50
- CVKD $32.00
- AVG Volume (30 Days)
- DRIO 138.4K
- CVKD 23.6K
- Earning Date
- DRIO 05-14-2025
- CVKD 05-08-2025
- Dividend Yield
- DRIO N/A
- CVKD N/A
- EPS Growth
- DRIO N/A
- CVKD N/A
- EPS
- DRIO N/A
- CVKD N/A
- Revenue
- DRIO $28,034,000.00
- CVKD N/A
- Revenue This Year
- DRIO $16.54
- CVKD N/A
- Revenue Next Year
- DRIO $21.93
- CVKD N/A
- P/E Ratio
- DRIO N/A
- CVKD N/A
- Revenue Growth
- DRIO 47.20
- CVKD N/A
- 52 Week Low
- DRIO $0.50
- CVKD $5.70
- 52 Week High
- DRIO $1.55
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- DRIO 50.29
- CVKD 50.87
- Support Level
- DRIO $0.63
- CVKD $13.00
- Resistance Level
- DRIO $0.72
- CVKD $15.87
- Average True Range (ATR)
- DRIO 0.04
- CVKD 0.87
- MACD
- DRIO -0.00
- CVKD 0.13
- Stochastic Oscillator
- DRIO 65.14
- CVKD 72.41
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.